Stay updated with breaking news from Barry Ticho. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stoke Therapeutics (NASDAQ:STOK – Free Report) had its price target hoisted by Needham & Company LLC from $14.00 to $22.00 in a research note released on Tuesday morning, Benzinga reports. The firm currently has a buy rating on the stock. STOK has been the subject of several other research reports. JPMorgan Chase & Co. increased […]
Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target […]
Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) insider Barry Ticho sold 10,000 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the sale, the insider now owns 6,981 shares of the company’s […]
Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has been given an average rating of “Moderate Buy” by the eight research firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month […]
– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support...